ArticleEmerging infectious diseases2018
Toxoplasmosis in Transplant Recipients, Europe, 2010-2014.
Article in Emerging infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 137 citations in OpenAlex.
- Toxoplasmosis in patients with an autoimmune disease and immunosuppressive agents: A multicenter study and literature review.PLoS neglected tropical diseases · 2022Pooled it
- Anti-Toxoplasma IgG assays: What performances for what purpose? A systematic review.Parasite (Paris, France) · 2021Pooled it
- Gaps in guidelines implementation and need for harmonization in toxoplasmosis management after allogeneic stem cell transplantation across EBMT centers: an Infectious Diseases Working Party survey.Bone marrow transplantation · 2026Article
- Cerebral Toxoplasmosis in a Renal Transplant Recipient-A Rare Complication.Life (Basel, Switzerland) · 2026Article
- Usefulness and Limitations of Polymerase Chain Reaction (PCR) for the Diagnosis and Management of Toxoplasmosis Following Allogeneic Hematopoietic Cell Transplant: Single-center Experience With 31 Patients Over 16 Years.Open forum infectious diseases · 2025Article
- Seroprevalence and risk factors forParasite epidemiology and control · 2025Review
- The prevalence and associated risk factors of post-transplant Toxoplasma gondii infection among kidney transplant recipients and patients with uremia in Central-southern China.PLoS neglected tropical diseases · 2025Article
- Diagnostic Approach to Pneumonia in Immunocompromised Hosts.Journal of clinical medicine · 2025Review
- Serological Profile of Anti-Tropical medicine and infectious disease · 2025Article
- Seroepidemiology ofCaspian journal of internal medicine · 2025Article
- In silico study to explore the mechanism of Toxoplasma-induced inflammation and target therapy based on sero and salivary Toxoplasma.Scientific reports · 2024Article
- Molecular diagnosis of human toxoplasmosis: the state of the art.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Review
- Emerging and Reemerging Parasitic Diseases in Taiwan: A Retrospective Study of Clinical Case Reports in 2001~2018.Pathogens (Basel, Switzerland) · 2024Article
- Toxoplasma gondii molecular detection and phylogenetic analysis in hemodialysis patients from Khuzestan, Southwest Iran.Tropical medicine and health · 2024Article
- Outcomes of Kidney Transplants From Toxoplasma-Positive Donors: An Organ Procurement and Transplant Network Database Analysis.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Article
- Iron-overload-induced ferroptosis in mouse cerebral toxoplasmosis promotes brain injury and could be inhibited by Deferiprone.PLoS neglected tropical diseases · 2023Article
- Review
- Article
- Toxoplasmosis: Current and Emerging Parasite Druggable Targets.Microorganisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 2 institutions in 1 country.
Funding
Abstract
Transplantation activity is increasing, leading to a growing number of patients at risk for toxoplasmosis. We reviewed toxoplasmosis prevention practices, prevalence, and outcomes for hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT; heart, kidney, or liver) patients in Europe. We collected electronic data on the transplant population and prevention guidelines/regulations and clinical data on toxoplasmosis cases diagnosed during 2010-2014. Serologic pretransplant screening of allo-hematopoietic stem cell donors was performed in 80% of countries, screening of organ donors in 100%. SOT recipients were systematically screened in 6 countries. Targeted anti-Toxoplasma chemoprophylaxis was heterogeneous. A total of 87 toxoplasmosis cases were recorded (58 allo-HSCTs, 29 SOTs). The 6-month survival rate was lower among Toxoplasma-seropositive recipients and among allo-hematopoietic stem cell and liver recipients. Chemoprophylaxis improved outcomes for SOT recipients. Toxoplasmosis remains associated with high mortality rates among transplant recipients. Guidelines are urgently needed to standardize prophylactic regimens and optimize patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.